Hydrogen Research Study
← Back to Research Library
Human Clinical StudyOther or not reported

Inhalation of hydrogen gas attenuates cisplatin-induced ototoxicity via reducing oxidative stress.

Juan Qu, Xu Li, Juan Wang, Wenjuan Mi, Keliang Xie, Jianhua Qiu · International journal of pediatric otorhinolaryngology · 2012

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Radiation and Chemotherapy Injury
Publication type Human Clinical Study
Hydrogen method Other or not reported

H2HUBB TAKEAWAY

In H(2) treatment was given twice with 2% H(2) inhalation for 60 min starting at 1h and 6h after cisplatin or saline injection, respectively, cisplatin significantly increased the levels of malondialdehyde (MDA) and 8-iso-prostaglandin F2α (8-iso-PGF2α) in serum and cochlear tissue, which was attenuated by H(2) treatment. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation.

What the Findings Mean

H2HUBB reviewed how molecular hydrogen affected the outcomes measured in H(2) treatment was given twice with 2% H(2) inhalation for 60 min starting at 1h and 6h after cisplatin or saline injection, respectively. Cisplatin significantly increased the levels of malondialdehyde (MDA) and 8-iso-prostaglandin F2α (8-iso-PGF2α) in serum and cochlear tissue, which was attenuated by H(2) treatment.

What the Researchers Studied

The researchers studied H(2) treatment was given twice with 2% H(2) inhalation for 60 min starting at 1h and 6h after cisplatin or saline injection, respectively. The study used a human clinical study.

What Effects Did Molecular Hydrogen Have?

Reported treatment duration: 60 min. Cisplatin significantly increased the levels of malondialdehyde (MDA) and 8-iso-prostaglandin F2α (8-iso-PGF2α) in serum and cochlear tissue, which was attenuated by H(2) treatment. The authors concluded that these results demonstrate that H(2) is beneficial to cisplatin-induced ototoxicity via reducing oxidative stress.

Why These Findings Matter

These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation and contribute to the growing body of molecular-hydrogen research.

How Strong Is This Evidence?

This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.

Technical Study Details

H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was H(2) treatment was given twice with 2% H(2) inhalation for 60 min starting at 1h and 6h after cisplatin or saline injection, respectively. The study used a human clinical study. The reported treatment duration was 60 min.

Limitations and Safety

No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.